

CRO Communiqué
Keeping you informed about CRO progress
June, 2011

Top Enrolling Physicians for grant year 6/1/2010 – 5/31/2011

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bonebrake	27	17	8.5	25.5
Dr. Ellis	16	11	4.5	15.5
Dr. Williams	16	13	2.5	15.5
Dr. Holden	11	9.3	1.5	10.8
Dr. Raju	11	4	6.5	10.5

May, the last month of our grant year was our best month for enrollments. We had 29 enrollments resulting in 8.3 cancer treatment credits and 13.6 cancer control credits. Dr. Jay Carlson contributed 10 enrollments in his first month with us at CRO. His friendly competitor, Dr. Bonebrake came in with 7 enrollments this month resulting in 7.0 cancer control credits! He finished as our top enroller of the year with 27 registrations. Drs. Ellis and Williams also friendly competitors ended up tied for the year. Drs Holden and Raju were just fractions apart. I wonder who will be our top enrolling investigators next year. Finishing out our grant year we have 104.7 treatment credits and 62.8 cancer control credits. We are short 15.3 in reaching our NCI target treatment goal of 120 and 7.2 short in reaching our NCI target cancer control goal of 70. Thanks to all you top enrolling investigators.

St. John's and Freeman CRO Affiliates in Joplin

Our hearts are all saddened by the devastating effects the EF5 tornado brought to our affiliates at St. John's and Freeman in Joplin last week. As we all know, St. John's hospital was destroyed in the storm. We are all grateful all our Joplin investigators and nurses are safe. Our hearts and prayers are with Lois Crockett, research nurse at Freeman who lost her home, car and worldly belongings. CRO has been in contact with NCI and keeping them updated on the progress in securing our drugs and records. We hope they are safe, dry and salvageable at St. John's.

Study Profile for May

CTSU ECOG E3108 "A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen" is May's study to profile. Patients must have Stage III/locally advanced or metastatic carcinoma of the breast where surgery is not possible. They must not have had chemotherapy or trastuzumab (Herceptin) for metastatic disease. Prior tamoxifen or other agents that modulate the estrogen receptor are not allowed. Non-protocol concurrent hormonal therapy is not allowed. Concurrent chemotherapy is not allowed. Patients with a history of central nervous system metastasis are allowed provided they have been treated at least 4 weeks prior to initiating study drug and do not require medications to control symptoms.

Phelps County Regional Hospital a New CRO Affiliate

It is official! A contract has been signed with Phelps County Regional Hospital in Rolla to enroll patients into CRO NCI research trials. It is great to add them as our fifth affiliate. Phelps County Administration is currently interviewing for a research nurse whose position will be paid with endowment money. Once they have a research nurse in place, CRO will work to train him/her to assist Dr. Bond and Dr. Nevils with enrolling patients.

CRO Research Drugs Moved to the CRO Administrative Office

CRO research drugs were moved from Convenient Care Pharmacy to the CRO Administrative office on May 31. CRO staff at the CRO Administrative office will now be ordering and receiving drugs needed for clinical trials.

New Studies Approved in May 2011

Opened at St. John's only

CTSU CALGB 50604 Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

CTSU ECOG E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

GOG 0238 A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus

GOG 0256 A Prospective Study of Cognitive Function During Chemotherapy for the Front Line Treatment of Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

SWOG S0816 A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Interim FDG-PET Imaging

SWOG S1005 A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer

Opened at Cox

No new studies approved at Cox

Studies Closed in May

Studies closed at Cox only

GOG 0224 A Randomized Phase II Evaluation of Continuous Progestin Therapy Vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From A Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation

GOG 0259 Nurse-delivered WRITE Symptoms© vs. Self-directed WRITE Symptoms© vs. Care as Usual for Optimal Symptom Management for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Closed studies at St. John's

No studies closed at St. John's